TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Tryptamine Therapeutics ( (AU:TYP) ).
Tryptamine Therapeutics Limited announced the successful conclusion of its Annual General Meeting, where all resolutions were passed with the required majorities. The company is making significant strides in its clinical trials, having completed studies for binge eating disorder and fibromyalgia, and initiating a new trial for irritable bowel syndrome. These developments position Tryptamine as a key player in the biotechnology sector, potentially enhancing its market presence and offering promising therapeutic solutions for conditions with unmet medical needs.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin, in combination with psychotherapy, to treat diseases with unmet medical needs. The company is advancing its lead program, TRP-8803, which is an IV-infused psilocin formulation aimed at improving the efficacy and safety of psychedelic therapies. Tryptamine has completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is currently conducting a trial for irritable bowel syndrome.
Average Trading Volume: 2,479,094
Technical Sentiment Signal: Buy
Current Market Cap: A$53.43M
See more insights into TYP stock on TipRanks’ Stock Analysis page.